GNLX
Genelux Corporation Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$118.73M
P/E Ratio
—
EPS
$-0.83
Beta
0.46
52W High
$8.54
52W Low
$2.21
50-Day MA
$2.64
200-Day MA
$3.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | 8,000 |
| Gross Profit (TTM) | 8,000 |
| EBITDA | $-32.97M |
| Operating Margin | -117650.00% |
| Return on Equity | -170.00% |
| Return on Assets | -77.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.31 |
| Price-to-Book | 9.97 |
| Price-to-Sales (TTM) | 14841.93 |
| EV/Revenue | 12780.12 |
| EV/EBITDA | -327.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.30% |
| Shares Outstanding | $44.81M |
| Float | $36.19M |
| % Insiders | 10.77% |
| % Institutions | 29.78% |
Analyst Ratings
Consensus ($17.50 target)
1
Strong Buy5
BuyData last updated: 4/8/2026